Seeking Alpha
Profile| Send Message| ()  

<< Back to Part III

This is Part IV of earnings being reported on Wednesday. There are quite a few market moving stocks reporting earnings. The stocks listed are not all those reporting, but stocks I believe are worth watching for a trade, investment, and/or to gauge market sentiment. It is easy to see we are in the middle of earnings season when it takes this many parts to go over the biggest companies reporting in one day.

Wellpoint, Inc (WLP) is a $27.32 billion market cap company. WellPoint is a health benefits company in terms of medical membership in the United States. As of December 31, 2010, it served 33.3 million medical members through its affiliated health plans and a total of 69.2 million individuals through all subsidiaries. The company reported (basic) $2.48 per share in earnings for the quarter ending March 31. The next reporting quarter estimated mean earnings are $1.8 per share. Analyst estimates range between $1.64 and $1.94 per share.

The current trailing 12 months (ttm) P/E ratio is 10.056 and the forward P/E ratio is 9.57. The falling P/E ratio is the result of future expected earnings increasing relative to the current price, and suggests bullishness in the company by investors . The stock has a price to book ratio (ttm) of 0.99. The price to sales ratio is 0.4. The chart doesn't look quite as good, but not bad either. The 60-day moving average is above the 200-day MA, and the price is above the 200-day MA. The 200-day MA is also rising. On the negative side is the fact that the price has broken down below the 60-day MA, which is also rounding down. If I owned this stock I would look into writing call options for a small level of protection, and maybe buying put options if cheap. I would not short here though.

[Click all to enlarge]

In the last month, the stock has moved in price -3.78%, with a one year change of 41.84%. Comparing to the S&P500 price change, Wellpoint's performance is -9.26% vs. the S&P 500 from a month ago, and the one year difference is 15.34% vs. S&P 500 price change. The annual growth rate of revenue is -9.57%. For the trailing 12 months investors received $0 in dividends for a yield of 1.34%.
Wellpoint has falling revenue year-over-year of $58.80 billion for 2010 vs. $65.03 billion for 2009. The bottom line has falling earnings year-over-year of $2.89 billion for 2010 vs. $4.75 billion for 2009. The company's earnings before income and taxes are falling with an EBIT year-over-year of $4.35 billion for 2010 vs. $7.40 billion for 2009.

Here is a look at reported earnings (some one time items are often excluded in reported EPS) compared to the mean estimate. Dollar differences are rounded to the nearest penny and percentage differences are rounded based on rounded dollar differences.

Fiscal Quarter Ending Month-YR Estimate Actual Difference Difference %
Mar-111.872.350.4825.64%
Dec-101.221.330.118.7%
Sep-101.581.740.1610.2%
Jun-101.551.670.127.81%
Mar-101.671.950.2816.42%

Northrop Grumman Corp. (NOC) is a $18.09 billion market cap integrated enterprise consisting of businesses that cover the entire security spectrum, from undersea to outer space and into cyberspace. The company reported (basic) $1.82 per share in earnings for the quarter ending March 31. The Quick Ratio is 1.04.

The next reporting quarter estimated mean earnings are $1.67 per share. Analyst estimates range between $1.56 and $1.74 per share. The current trailing 12 months (ttm) P/E ratio is 9.263 and the forward P/E ratio is 9.06. The stock has a price to book ratio (ttm) of 1.31. The price to sales ratio is 0.51.

In the last month, the stock has moved in price -1.63%, with a one year change of 24.26%. Comparing to the S&P500 price change, Northrop Grumman's performance is -7.23% vs. the S&P 500 from a month ago, and the one year difference is 1.04% vs. S&P 500 price change. The annual growth rate of revenue is 2.97%. The last fiscal year had accounts receivable to sales percentage of 0.1167% compared to the same period a year earlier of 0.1005%. For the trailing 12 months investors received $1.81 in dividends for a yield of 3.06%.

Northrop Grumman has rising revenue year-over-year of $34.76 billion for 2010 vs. $33.76 billion for 2009. The bottom line has rising earnings year-over-year of $2.05 billion for 2010 vs. $1.69 billion for 2009. The company's earnings before income and taxes are rising with an EBIT year-over-year of $3.07 billion for 2010 vs. $2.48 billion for 2009. Here is a look at reported earnings (some one time items are often excluded in reported EPS) compared to the mean estimate. Dollar differences are rounded to the nearest penny and percentage differences are rounded based on rounded dollar differences.

Fiscal Quarter Ending Month-YR Estimate Actual Difference Difference %
Mar-111.561.670.117.27%
Dec-101.011.270.2625.95%
Sep-101.461.640.1812.52%
Jun-102.192.340.156.71%
Mar-101.321.510.1914.58%

Moodys Corp. (MCO) is a $8.47 billion market cap provider of credit ratings; credit and economic related research, data and analytical tools, risk management software and quantitative credit risk measures, credit portfolio management solutions, training and financial credentialing and certification services. The company reported (basic) $0.68 per share in earnings for the quarter ending March 31. The Quick Ratio is 1.44.

The next reporting quarter estimated mean earnings are $0.57 per share. Analyst estimates range between $0.54 and $0.59 per share. The current trailing 12 months (ttm) P/E ratio is 15.906 and the forward P/E ratio is 14.49. The falling P/E ratio is the result of future earnings increasing relative to the current price and suggests bullishness in the company by analysts. The price to sales ratio is 3.09.

In the last month, the stock has moved in price 0.32%, with a one year change of 65.57%. Comparing to the S&P500 price change, Moody's performance is -5.39% vs. the S&P 500 from a month ago, and the one year difference is 34.63% vs. S&P 500 price change. The annual growth rate of revenue is 13.06%. The last fiscal year had accounts receivable to sales percentage of 0.2448% compared to the same period a year earlier of 0.2476%. For the trailing 12 months investors received $0.44 in dividends for a yield of 1.51%.

Moodys has rising revenue year-over-year of $2.03 billion for 2010 vs. $1.80 billion for 2009. The bottom line has rising earnings year-over-year of $507.80 million for 2010 vs. $402.00 million for 2009. The company's earnings before income and taxes are rising with an EBIT year-over-year of $772.80 million for 2010 vs. $687.50 million for 2009.

Here is a look at reported earnings (some one time items are often excluded in reported EPS) compared to the mean estimate. Dollar differences are rounded to the nearest penny and percentage differences are rounded based on rounded dollar differences.

Fiscal Quarter Ending Month-YR Estimate Actual Difference Difference %
Mar-110.540.670.1324.47%
Dec-100.480.50.023.63%
Sep-100.450.510.0612.91%
Jun-100.440.490.0511.8%
Mar-100.440.470.037.63%

PDL Biopharma, Inc. (PDLI) is a $886.97 million market cap company. PDL is engaged in the management of its antibody humanization patents and royalty assets, which consist of its Queen, et al. patents and license agreements with pharmaceutical and biotechnology companies. The company reported (basic) $0.32 per share in earnings for the quarter ending March 31. The Quick Ratio is 1.47.

The next reporting quarter estimated mean earnings are $0.4 per share. Analyst estimates range between $0.38 and $0.42 per share. The current trailing twelve months (ttm) P/E ratio is 9.859 and the forward P/E ratio is 4.67. The falling P/E ratio is the result of future earnings increasing relative to the current price and suggests bullishness in the company by analysts. The price to sales ratio is 3.23.

In the last month the stock has moved in price 23.78%, with a one year change of 29.38%. Comparing to the S&P500 price change, PDL Biopharma, Inc.'s performance is 1.69% vs. the S&P 500 from a month ago, and the one year difference is 1.99% vs. S&P 500 price change. The annual growth rate of revenue is 8.42%. The last fiscal year had accounts receivable to sales percentage of 0.0014% compared to the same period a year earlier of 0.0033%. For the trailing 12 months investors received $0.73 in dividends for a yield of 9.45%.

PDL Biopharma, Inc. has rising revenue year-over-year of $344.98 million for 2010 vs. $318.18 million for 2009. The bottom line has falling earnings year-over-year of $91.87 million for 2010 vs. $189.66 million for 2009. The company's earnings before income and taxes are falling with an EBIT year-over-year of $211.08 million for 2010 vs. $297.12 million for 2009.

Here is a look at reported earnings (some one time items are often excluded in reported EPS) compared to the mean estimate. Dollar differences are rounded to the nearest penny and percentage differences are rounded based on rounded dollar differences.

Fiscal Quarter Ending Month-YR Estimate Actual Difference Difference %
Mar-110.240.250.013.56%
Dec-100.210.2-0.01-5.39%
Sep-100.250.24-0.01-4.53%
Jun-100.380.3-0.08-21.94%
Mar-100.230.15-0.08-34.78%

Lam Research Corp. (LRCX) is a $5.51 billion market cap supplier of wafer fabrication equipment and services to the worldwide semiconductor industry. The company designs, manufactures, markets, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company reported (basic) $1.47 per share in earnings for the quarter ending March 27. The Quick Ratio is 2.57.

The next reporting quarter estimated mean earnings are $1.09 per share. Analyst estimates range between $1.07 and $1.12 per share. The current trailing 12 months (ttm) P/E ratio is 7.486 and the forward P/E ratio is 8.95. A rising P/E ratio is usually not what we want to see for an investment. The stock has a price to book ratio (ttm) of 2.92. The price to sales ratio is 2.42.

In the last month, the stock has moved in price 13.44%, with a one year change of 17.78%. Comparing to the S&P500 price change, Lam Research's performance is 3.95% vs. the S&P 500 from a month ago, and the one year difference is 5.31% vs. S&P 500 price change. The annual growth rate of revenue is 91.21%. The last fiscal year had accounts receivable to sales percentage of 0.2343% compared to the same period a year earlier of 0.2272%.

Lam Research has rising revenue year-over-year of $2.13 billion for 2010 vs. $1.12 billion for 2009. The bottom line has rising earnings year-over-year of $346.67 million for 2010 vs. $-302.15 million for 2009. The company's earnings before income and taxes are rising with an EBIT year-over-year of $425.41 million for 2010 vs. $-281.24 million for 2009.

Here is a look at reported earnings (some one time items are often excluded in reported EPS) compared to the mean estimate. Dollar differences are rounded to the nearest penny and percentage differences are rounded based on rounded dollar differences.

Fiscal Quarter Ending Month-YR Estimate Actual Difference Difference %
Mar-111.361.450.096.96%
Dec-101.571.740.1711.02%
Sep-101.371.520.1510.55%
Jun-100.971.170.221.19%
Mar-100.820.940.1214.61%

CNO Financial Group, Inc. (CNO) is a $1.96 billion market cap holding company for a group of insurance companies operating throughout the United States that develop, market and administer supplemental health insurance, annuity, individual life insurance and other insurance products. The company reported (basic) $0.21 per share in earnings for the quarter ending March 31. The next reporting quarter estimated mean earnings are $0.18 per share. Analyst estimates range between $0.17 and $0.18 per share.

The current trailing 12 months (ttm) P/E ratio is 7.39 and the forward P/E ratio is 9.58. A rising P/E ratio is usually not what we want to see for an investment. The stock has a price to book ratio (ttm) of 0.47. The price to sales ratio is 0.5.

In the last month, the stock has moved in price 7.87%, with a one year change of 50.48%. Comparing to the S&P500 price change, CNO Financial Group, Inc.'s performance is 1.73% vs. the S&P 500 from a month ago, and the one year difference is 22.36% vs. S&P 500 price change. The annual growth rate of revenue is -5.93%.

CNO Financial Group, Inc. has falling revenue year-over-year of $4.08 billion for 2010 vs. $4.34 billion for 2009. The bottom line has rising earnings year-over-year of $284.60 million for 2010 vs. $85.70 million for 2009. The company's earnings before income and taxes are rising with an EBIT year-over-year of $293.50 million for 2010 vs. $173.60 million for 2009.

Here is a look at reported earnings (some one time items are often excluded in reported EPS) compared to the mean estimate. Dollar differences are rounded to the nearest penny and percentage differences are rounded based on rounded dollar differences.

Fiscal Quarter Ending Month-YR Estimate Actual Difference Difference %
Mar-110.160.180.029.36%
Dec-100.160.180.0216.05%
Sep-100.150.160.017.89%
Jun-100.130.160.0318.96%
Mar-100.130.140.0111.29%

Ameriprise Financial Inc (AMP) is a $13.42 billion market cap holding company primarily engaged in business through its subsidiaries. It provides financial planning, and products and services. The company reported (basic) $0.96 per share in earnings for the quarter ending March 31. The next reporting quarter estimated mean earnings are $1.33 per share. Analyst estimates range between $1.29 and $1.42 per share.

The current trailing 12 months (ttm) P/E ratio is 12.552 and the forward P/E ratio is 8.31. The falling P/E ratio is the result of future earnings increasing relative to the current price and suggests bullishness in the company by analysts. The stock has a price to book ratio (ttm) of 1.41. The price to sales ratio is 1.5.

In the last month, the stock has moved in price -0.04%, with a one year change of 42.62%. Comparing to the S&P500 price change, Ameriprise Financial's performance is -5.73% vs. the S&P 500 from a month ago, and the one year difference is 15.97% vs. S&P 500 price change. The annual growth rate of revenue is 26.43%. For the trailing 12 months investors received $0.71 in dividends for a yield of 1.66%.

Ameriprise Financial Inc has rising revenue year-over-year of $10.05 billion for 2010 vs. $7.95 billion for 2009. The bottom line has rising earnings year-over-year of $1.10 billion for 2010 vs. $722.00 million for 2009. The company's earnings before income and taxes are rising with an EBIT year-over-year of $1.66 billion for 2010 vs. $1.06 billion for 2009.

Here is a look at reported earnings (some one time items are often excluded in reported EPS) compared to the mean estimate. Dollar differences are rounded to the nearest penny and percentage differences are rounded based on rounded dollar differences.

Fiscal Quarter Ending Month-YR Estimate Actual Difference Difference %
Mar-111.321.350.031.95%
Dec-101.311.21-0.1-7.87%
Sep-101.071.370.328.18%
Jun-100.771.10.3343.49%
Mar-100.810.8100.00%

Interdigital, Inc. (IDCC) is a $3.31 billion market cap holding company, and its various subsidiaries engage in technology research and development activities or in the prosecution, maintenance, enforcement, and licensing of patents. The company reported (basic) $0.52 per share in earnings for the quarter ending March 31. The Quick Ratio is 3.47. The next reporting quarter estimated mean earnings are $0.36 per share. Analyst estimates range between $0.32 and $0.38 per share.

The current trailing 12 months (ttm) P/E ratio is 25.106 and the forward P/E ratio is 24.17. The falling P/E ratio is the result of future earnings increasing relative to the current price and suggests bullishness in the company by analysts. The stock has a price to book ratio (ttm) of 5.29. The price to sales ratio is 4.73.

In the last month, the stock has moved in price 17.08%, with a one year change of 22.99%. Comparing to the S&P500 price change, Interdigital, Inc.'s performance is 4.64% vs. the S&P 500 from a month ago, and the one year difference is 6.84% vs. S&P 500 price change. The annual growth rate of revenue is 32.66%. The last fiscal year had accounts receivable to sales percentage of 0.0852% compared to the same period a year earlier of 0.7159%. For the trailing 12 months investors received $0 in dividends for a yield of 0.55%.

Interdigital, Inc. has rising revenue year-over-year of $394.55 million for 2010 vs. $297.40 million for 2009. The bottom line has rising earnings year-over-year of $153.62 million for 2010 vs. $87.26 million for 2009. The company's earnings before income and taxes are rising with an EBIT year-over-year of $235.87 million for 2010 vs. $113.89 million for 2009.

Here is a look at reported earnings (some one time items are often excluded in reported EPS) compared to the mean estimate. Dollar differences are rounded to the nearest penny and percentage differences are rounded based on rounded dollar differences.

Fiscal Quarter Ending Month-YR Estimate Actual Difference Difference %
Mar-110.500.530.034.95%
Dec-100.790.76-0.03-3.8%
Sep-100.720.790.079.22%
Jun-100.610.780.1727.87%
Mar-101.211.09-0.12-10.16%

Owens Illinois Inc. (OI) is a $4.4 billion market cap manufacturer of glass containers with 81 glass manufacturing plants in 21 countries. It produces glass containers for beer, ready-to-drink low alcohol refreshers, spirits, wine, food, tea, juice and pharmaceuticals. The company also produces glass containers for soft drinks and other non-alcoholic beverages outside the United States. The company reported (basic) $0.44 per share in earnings for the quarter ending March 31. The Quick Ratio is 0.86.

The next reporting quarter estimated mean earnings are $0.62 per share. Analyst estimates range between $0.47 and $0.66 per share. The current trailing 12 months (ttm) P/E ratio is 17.762 and the forward P/E ratio is 8.54. The falling P/E ratio is the result of future earnings increasing relative to the current price and suggests bullishness in the company by analysts. The stock has a price to book ratio (ttm) of 2.84. The price to sales ratio is 0.78.

In the last month, the stock has moved in price 4.89%, with a one year change of -9.55%. Comparing to the S&P500 price change, Owen's performance is -1.08% vs. the S&P 500 from a month ago, and the one year difference is -26.45% vs. S&P 500 price change. The annual growth rate of revenue is -0.29%. The last fiscal year had accounts receivable to sales percentage of 0.1621% compared to the same period a year earlier of 0.1478%.

Owens has falling revenue year-over-year of $6.63 billion for 2010 vs. $6.65 billion for 2009. The bottom line has falling earnings year-over-year of $-47.00 million for 2010 vs. $162.00 million for 2009. The company's earnings before income and taxes are rising with an EBIT year-over-year of $796.00 million for 2010 vs. $784.00 million for 2009.

Here is a look at reported earnings (some one time items are often excluded in reported EPS) compared to the mean estimate. Dollar differences are rounded to the nearest penny and percentage differences are rounded based on rounded dollar differences.

Fiscal Quarter Ending Month-YR Estimate Actual Difference Difference %
Mar-110.460.510.0511.35%
Dec-100.470.45-0.02-3.95%
Sep-100.860.90.044.75%
Jun-100.910.9-0.01-1.32%
Mar-100.470.50.035.73%
Source: 9 Companies to Consider That Are Reporting Earnings on Wednesday, Part IV